RNA - NASDAQ
Atrium Therapeutics, Inc.
$12.17
-1.3%Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
At a Glance
Live SnapshotAtrium Therapeutics, Inc. Management Team
Mr. Eric B. Mosbrooker
Chief Commercial Officer
Compensation
$45,000
Mr. Michael F. MacLean CPA
Chief Financial Officer
Compensation
$839,110
Ms. Teresa McCarthy
Chief Human Resources Officer
Compensation
$782,410
Mr. John B. Moriarty Jr., ESQ., J.D.
Chief Legal Officer & Corporate Secretary
Compensation
$683,588
Dr. Steven George Hughes M.B.A., M.D.
Chief Medical Officer
Ms. Kathleen P. Gallagher
Chief Program Officer
Dr. W. Michael F. Flanagan Ph.D.
Chief Scientific Officer
Compensation
$855,110
Mr. Charles Calderaro III
Chief Technical Officer
Dr. Troy Edward Wilson J.D., Ph.D.
Co-Founder & Independent Chairman
Compensation
$71,908
Ms. Sarah Boyce
President, Chief Executive Officer & Director
Compensation
$1,270,910
Dr. Frank P. McCormick Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Prof. Mark E. Davis Ph.D.
Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
Atrium Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $19.97M worth of RNA shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
25.4K
1.83M
-1.8M
-$1.83M
6-9 Months
0
0.00
67.5K
2.97M
-3.0M
-$2.97M
9-12 Months
0
0.00
330.0K
15.17M
-15.2M
-$15.17M
Top Buyers
No buying activity
Top Sellers
Levin Arthur A
Director
$5.12M
Boyce Sarah
Director, Officer: President And Ceo
$4.35M
Mccarthy Teresa
Officer: Chief Human Resources Officer
$2.23M
Hughes Steven George
Officer: Chief Medical Officer
$2.21M
Flanagan W. Michael
Officer: Chief Scientific Officer
$1.61M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $19.97M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
RNA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | April 29, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | April 26, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 16, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.